[8-K] Health In Tech, Inc. Reports Material Event
Rhea-AI Filing Summary
Health In Tech, Inc. furnished an investor presentation describing its AI-powered marketplace that helps small and mid-sized businesses access self-funded health plans without taking plan or underwriting risk. The company reported 2025 revenue of $33.3M, up from $19.5M in 2024, and 2025 adjusted EBITDA of $4.1M versus $2.3M a year earlier. As of December 31, 2025, it had 22,515 enrolled employees, 795 business clients, and 858 brokers and agencies, with stockholders’ equity of $17.1M. The presentation reiterates 2026 revenue guidance of $45M–$50M, highlights a fee-based model with no claims exposure, and emphasizes plans to drive growth through more brokers, products, and carrier relationships.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
The (Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On March 25, 2026, Health In Tech, Inc., a Nevada corporation (the “Company”) prepared an investor presentation that officers and other representatives of the Company intend to present at conferences and meetings. A copy of the investor presentation is furnished as Exhibit 99.1 of this Current Report on Form 8-K. The information set forth in this Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
Certain statements in this Current Report on Form 8-K or in the accompanying exhibits are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in its forward-looking statements are set forth in the “Risk Factors” section in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the SEC, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity. Health In Tech undertakes no obligation to update any forward-looking statements, except as required by law.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit No. | Description | |
| 99.1 | Investor Presentation. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: March 27, 2026 | ||
| HEALTH IN TECH, INC. | ||
| By: | /s/ Tim Johnson | |
| Name: | Tim Johnson | |
| Title: | Chief Executive Officer | |
2
Exhibit 99.1
An AI-Powered Marketplace Platform Helping SMBs Access Better Self-Funded Health Plans
Disclaimer & Safe Harbor This presentation has been prepared by the Health In Tech, Inc. (the "Company," "Health In Tech," "HIT," "we," "our," or "us") solely for informational purposes. The information included herein in this presentation has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. By viewing or accessing the information contained in this presentation, you acknowledge and agree that to the fullest extent permitted by law, none of the Company or any of its affiliates, advisers or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. Industry and market data used in this presentation have been obtained from third -party industry publications and sources as well as from research reports prepared for other purposes. The company has not independently verified the data obtained from the sources and cannot assure you of the data's accuracy or completeness. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed. None of the Company or any of its affiliates, advisers or representatives make any undertaking to update any such information subsequent to the date hereof. This presentation should not be construed as legal, tax, investment or other advice. This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, nor shall there be any sale of securities in any state or other jurisdiction to any person or entity to which it is unlawful to make such offer, solicitation or sale in such state or jurisdiction. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. In evaluating its business, the Company uses certain non-GAAP measures as supplemental measures to review and assess its operating and financial performance. These non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating and financial performances, investors should not consider them in isolation, or as a substitute for any consolidated statement of operations data prepared in accordance with U.S. GAAP. Reconciliation of any non-GAAP financial measures to their closest corresponding GAAP measures is provided in the Appendix to this presentation. This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding possible or assumed operational results, financial condition and outlook, business strategies and plans, market trends and opportunities, competitive position, industry environment and potential growth opportunities of the Company. These forward-looking statements are based on current expectations, estimates, forecasts and projections. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms and similar expressions that convey the uncertainty of future events or outcomes are intended to identify these forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Factors that could cause actual results to differ from those projected include, but are not limited to, the following: the Company's liquidity position and ability to access capital; the Company's ability to continue as a going concern; employee attrition and the Company's ability to retain senior management and other key personnel; the Company's ability to enhance its existing products and services; product and service quality issues; and market competition. Further information on these and other factors that could affect the Company's financial results is included in the reports on Form 10-K, Quarterly Reports on Form 10-Q and other periodic filings with the Securities and Exchange Commission from time to time. Because of the risks and uncertainties, the Company cautions you not to place undue reliance on these statements, which speak only as of the date of this presentation. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Except as expressly required by the federal securities laws, we undertake no obligation, and specifically disclaim any obligation, to release any revision to any forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events. 2
Health In Tech – Disrupting Healthcare Insurance Market (1) Sources: Centers for Medicare & Medicaid Services 2024 Data and IBISWorld Assessment: Health & Medical Insurance in the US - Market Size (2004-2032), available, respectively, at: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/historical & https://www.ibisworld.com/united-states/market-size/health-medical-insurance/1324/ (2) CAGR is calculated from 2022 to the Mid-Point of 2026 Revenue Guidance of $47.5M (3) This is not a projection or guarantee of future results but rather is solely the guidance the Company provided in connection with its fiscal year 2025 earnings release. The Company's actual results may vary significantly from this range. (4) As of Market Close 3/18/2026 HIT Helps Small & Medium Size Businesses ("SMBs") Access Cheaper Healthcare Faster Through its Proprietary Product Suite Operates in Massive Under-Penetrated Market(1) Proven, Scalable, Profitable, High Growth Business Fee Driven Business with No Plan or Underwriting Risk Exposure Highly Aligned Executive Leadership with Significant Ownership Revenue Revenue ($M's) Key Market Statistics(4) ~$106M Market Cap $1.83 Stock Price ~57.7M Shares Out. Nasdaq: HIT HQ: Stuart, FL 3 (3) (3)
I Business Overview
Problem: Access to Self-Funded Healthcare Plans (1) KFF 2025 Employer Health Benefit Survey (2) Intercept Health, "The Hidden Cost of Fully Insured Plans: Why Self-Funding Is Usually Better for Employers," 5 Businesses want the cost and flexibility benefits provided by Self-Funded Healthcare Plans ("SFPs") Health In Tech's AI-powered solutions remove barriers, enabling SMBs to benefit from SFPs Self-funded plans provide material benefits vs. fully insured plans. Complexity of successfully implementing self- funded plans has impacted market penetration, especially for small businesses with limited resources. Complexity of SFPs have made implementation unrealistic for many business 15 – 20% Self-Funded Plan Penetration %(1) Small Business 27% Large Business 80% Estimated Self-Funded Savings(2)
AI Powered Platform Enables Self-Funded Plan Penetration 6 Health In Tech makes self-funded health insurance more accessible by integrating health plan administration and stop loss underwriting into one unified platform
Tailored Coverage Starts with SMR: Intelligent Plan Design 7 P B M s B ro k er s T P A s H ea lt hc ar e N et w or k s Te le m ed C o m p a ni e s M e di c al M G M T C o m p a ni es C ar ri er s Plan Design & Customization Underwriting & Risk Assessment Provider Network Integration Manages relationship with brokers, third-party administrators ("TPAs"), and other vendors to create uniquely tailored cost saving plans Solves the complexity issue for SMBs Pulls understanding of vendor needs and capabilities into a singular clear platform
Bundle Self-Funded Health Plan + Stop-Loss Insurance (1) About 12 days for employer groups of 10–100 employees & about 3 months for groups exceeding 100 employees (2) About 2 minutes for employer groups of 10–100 employees & about two weeks for groups exceeding 100 employees 8 Legacy Quoting Procedures Bindable Proposal Presented 4 Tiers 12 Plans Plan Design & Customization Underwriting & Risk Assessment Provider Network Integration ~2 minutes to 2 weeks(2) ~12 days to 3 months(1) Applications Package Creation Quotes Final Quote Nurse Review Bindable Proposal eDIYBS is a proprietary software offering which allows brokers to access bindable self- funded plan quotes in minutes Speed and ease of bindable quotes allow for enhanced plan flexibility and cost savings Workflow is trained via proprietary healthcare data vs public data sets
Nationwide Coverage Powered by HI Performance Network (1) All numbers as of December 31, 2025. (2) https://advancedbenefitconsulting.com/reference-based-pricing-key-to-solving-health-insurance-industry-cost-issues/ 50 States(1) 1.30M+ Provider Locations (1) 9 Nationwide reach with direct Medicare – based contracts across 50 states (1) Seamless integration with HIT's platform enables real-time claims and care coordination Medicare-based pricing drives 20%+ average cost savings vs. traditional commercial rates (2) Plan Design & Customization Underwriting & Risk Assessment Provider Network Integration
Health In Tech makes self-funded health insurance more accessible by integrating health plan administration and stop loss underwriting into one unified platform How HIT Makes Money Today (1) Based on size of business (2) See Appendix & FY2025 10-K Self-funded Stop Loss Insurance Program for Employers (12- or 36-month term) = Stop Loss Insurance + Self-funded Healthcare Plan Plan designs and vendor management for employers Monthly Administrative Fee(1) Recurring Revenue over policy terms of 12 or 36 months Underwriting for Carriers % of stop-loss gross premiums 10 ~20% of Revenue in 2025(2) ~80% of Revenue in 2025(2)
HIT By The Numbers (1) Adjusted EBITDA represents our net income before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. Please refer to Appendix Slide 24 of this presentation for a reconciliation of Adjusted EBITDA to net income, the most comparable GAAP measurement, for the three and twelve months ended December 31, 2025. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance. (2) This is not a projection or guarantee of future results but rather is solely the guidance the Company provided in connection with its fiscal year 2025 earnings release. The Company's actual results may vary significantly from this range. As of December 31, 2025 40 States with Clients 795 Business Clients 850+ Brokers, TPAs and Additional Third-party Agencies Revenue Adj. EBITDA(1) 22,515 Enrolled Employees 2026 Revenue Guidance(2) $45M - $50M ~43% YoY Growth at the Midpoint 11 $7.5M +53% YoY $33.3M +71% YoY Q4 2025 FY 2025 $0.3M N/A $4.1M +81% YoY
What Health In Tech is NOT A Risk-Bearing Insurer or Carrier (HIT does not hold any plan risk) An Entity with Underwriting Risk (eDIYBS generates quotes/binds; carriers & stop-loss providers bear the risk) Liable for Claims Outcomes (HIT has zero financial exposure) Exposed to Catastrophic Losses (Stone Mountain Risk models & delivers stop- loss protection; HIT enables only) HIT has NO Plan Risk Exposure Pure-opportunity model: Tech-enabled, fee-based, scalable upside with zero downside from claims or risk 12
HIT is Powering and Accelerating AI Disruption 13 The Health In Tech marketplace wins — AI accelerates value inside our platform, not outside of it HIT is a marketplace platform uniting an ecosystem of vendors HIT is the platform disruptors use to access the marketplace and deliver growth Distribution and marketplace capabilities insulate HIT from single-vendor AI disruption
More Data Monetizing proprietary data lake will enhance cross-selling opportunities and entry into new markets More Products Introducing novel new products such as Three-Year Rate Stabilization Program, One Year Large Group, and others More Managing General Underwriters ("MGUs") & Carriers Driving MGUs onto the HIT platform to leverage AI-enabled underwriting feature Multiple Pathways to Drive Outsized Growth 14 More Brokers 1 2 3 4 HIT in-house sales team is focused on increasing awareness and driving broker count in 2026 and beyond
II Financials & Conclusion
Full Year 2025 Financial Highlights 16 $19.5 $33.3 2024 2025 2026E $45.0 Total Revenues ($ in millions) +71% $2.3 $4.1 TBD 2024 2025 2026E Adjusted EBITDA (1) ($ in millions) +81% +35% to +50% $50.0 (1) Please refer to Appendix Slide 24 of this presentation for a reconciliation of Adjusted EBITDA to net income, the most comparable GAAP measurement, for the years ended December 31, 2025 and 2024. (2) This is not a projection or guarantee of future results but rather is solely the guidance the Company provided in connection with its fiscal year 2025 earnings release. Company's actual results may vary significantly from this range. (2) (2)
Business Metrics 17 2024 2025 18,348 22,515 Number of Billed Enrolled Employees +23% 2024 2025 Brokers, TPAs and Agencies +34% 640 858 (As of December 31) (As of December 31)
Conclusions Platform removes complexity and provides novel AI-powered products and solutions Operating in massive, underserved market based on legacy structures Proven business model poised to drive outsized growth No plan risk or underwriting risk exposure Highly aligned leadership team 18 Revenue Revenue ($M's) (1) CAGR is calculated from 2022 to the Mid-Point of Revenue Guidance of $47.5M (2) This is not a projection or guarantee of future results but rather is solely the guidance the Company provided in connection with its fiscal year 2025 earnings release. The Company's actual results may vary significantly from this range. (2) (2)
III Appendix
Financial Results (1) Please refer to Appendix Slide 24 of this presentation for a reconciliation of Adjusted EBITDA to net income, the most comparable GAAP measurement, for the years ended December 31, 2025 and 2024. (2) This is not a projection or guarantee of future results but rather is solely the guidance the Company provided in connection with its fiscal year 2025 earnings release. The Company's actual results may vary significantly from this range. 20 Three Months Ended 12/31 Fiscal Year Ended 12/31 (In millions) 2025 2024 2025 2024 Total Revenue $7.5 $4.9 $33.3 $19.5 Gross Profit $4.1 $3.8 $20.9 $15.4 Gross Margin Percent 55.0% 77.4% 62.8% 79.2% Total Operating Expenses $4.3 $4.1 $19.4 $14.4 Net Income (Loss) $(0.3) $(0.1) $1.3 $0.7 Income before income tax expense $(0.4) $(0.1) $1.7 $0.9 Adjusted EBITDA (1) $0.3 $0.5 $4.1 $2.3
Quarterly Financial Highlights 21 $5.1 $8.0 $5.0 $9.3 $4.5 $8.5 $4.9 $7.5 Q1'24 Q1'25 Q2'24 Q2'25 Q3'24 Q3'25 Q4'24 Q4'25 Total Revenues ($ in millions) $0.5 $1.2 $0.7 $1.6 $0.7 $1.0 $0.5 $0.3 Q1'24 Q1'25 Q2'24 Q2'25 Q3'24 Q3'25 Q4'24 Q4'25 Adjusted EBITDA (1) ($ in millions) (1) Please refer to Appendix Slide 24 of this presentation for a reconciliation of Adjusted EBITDA to net income, the most comparable GAAP measurement, for the periods presented.
Balance Sheet Highlights 22 Cash and Cash Equivalents ($ in millions) Working Capital ($ in millions) Stockholders' Equity ($ in millions) $7.8 $7.7 12/31/24 12/31/25 $8.7 $10.2 12/31/24 12/31/25 $13.2 $17.1 12/31/24 12/31/25
From an already efficient baseline of 29 days in 2024, we drove a step-change improvement in cash conversion, reducing accounts receivable days to 14 Accounts Receivable Days 23 2023 2024 2025 Accounts Receivable Days 42 29 14
GAAP To Non-GAAP Reconciliation – Adjusted EBITDA(1) 24 Three Months Ended March 31, Three Months Ended June 30, Three Months Ended September 30, Three Months Ended December 31, Fiscal Year Ended December 31, (in dollars) 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Net income 498,592 100,536 630,631 338,007 452,176 376,086 (302,557) (144,152) 1,278,842 670,477 Interest (income) expense (85,366) 140,688 (108,198) 133,661 (111,699) 126,540 (104,659) (28,774) (409,922) 372,115 Amortization expense 135,983 134,787 135,983 134,787 217,981 135,584 410,630 135,983 900,577 541,141 Income tax (benefit) expense 185,831 91,198 202,637 63,268 148,046 30,653 (141,184) 33,404 395,330 218,523 Stock-based compensation expense 493,171 - 707,963 - 292,552 - 76,733 468,489 1,570,419 468,489 Provision for credit losses on other receivables - - - - - - 377,587 - 377,587 - Total net adjustments 729,619 366,673 938,385 331,716 546,880 292,777 619,107 609,102 2,833,991 1,600,268 Adjusted EBITDA 1,228,211 467,209 1,569,016 669,723 999,056 668,863 316,550 464,950 4,112,833 2,270,745 (1) Adjusted EBITDA represents our net income before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.
Filing Exhibits & Attachments
4 documentsPress Releases
